Drugs Affecting Blood and Blood Formation Practice Questions

Q: When heparin is given during pregnancy, it should be supplemented with which of the following?

Calcium. **Explanation:** **1. Why Calcium is the Correct Answer:** Heparin, when used for prolonged periods (typically >6 months), is associated with **Heparin-Induced Osteoporosis**. The underlying mechanism involves heparin increasing osteoclast activity and decreasing osteoblast function, leading to a reduction in bone mineral density. During pregnancy, the demand for calcium is already high to support fetal skeletal development. Therefore, to mitigate the risk of bone loss and fractures in the mother, **Calcium and Vitamin D supplementation** is mandatory when heparin is administered long-term. **2. Analysis of Incorrect Options:** * **A. Zinc:** While zinc is an essential trace element for fetal growth, it has no direct interaction with heparin therapy or its side effect profile. * **C. Folic acid:** Folic acid is routinely supplemented in pregnancy to prevent neural tube defects, but its requirement is not specifically linked to heparin administration. * **D. Ferrous sulphate:** Iron is supplemented to prevent gestational anemia. While important, it does not counteract the specific adverse effect of heparin on bone metabolism. **3. Clinical Pearls for NEET-PG:** * **Drug of Choice:** Low Molecular Weight Heparin (LMWH), such as Enoxaparin, is the anticoagulant of choice in pregnancy because it does not cross the placenta (non-teratogenic). * **Warfarin Contraindication:** Warfarin is contraindicated in pregnancy (especially the 1st trimester) as it is teratogenic, causing **Fetal Warfarin Syndrome** (nasal hypoplasia, stippled epiphyses). * **Monitoring:** While Unfractionated Heparin (UFH) requires aPTT monitoring, LMWH generally does not, though Anti-Xa levels may be monitored in high-risk pregnant patients. * **Side Effects:** Apart from osteoporosis, watch for **HIT (Heparin-Induced Thrombocytopenia)**, though the risk is lower with LMWH than with UFH.

Q: Oral anticoagulants given to pregnant women can cause which of the following fetal malformations?

Craniofacial malformation. **Explanation:** Oral anticoagulants, specifically **Warfarin** (a vitamin K antagonist), are known teratogens when administered during the first trimester (specifically between 6–9 weeks of gestation). This leads to a constellation of defects known as **Fetal Warfarin Syndrome (Warfarin Embryopathy).** **1. Why Craniofacial Malformation is Correct:** Warfarin crosses the placenta and interferes with the γ-carboxylation of proteins like osteocalcin, which are essential for bone and cartilage formation. The hallmark of this syndrome is **midfacial hypoplasia** (depressed nasal bridge) and **choanal atresia**. These are classic craniofacial malformations. Another pathognomonic feature is **stippled epiphyses** (chondrodysplasia punctata), primarily affecting the axial skeleton. **2. Why Other Options are Incorrect:** * **Long bones limb defect:** While Warfarin affects bone mineralization, it typically causes stippling of the epiphyses rather than gross limb reduction defects (which are more characteristic of Thalidomide). * **Cardiovascular malformation:** These are more commonly associated with Lithium (Ebstein’s anomaly) or poorly controlled maternal diabetes, rather than oral anticoagulants. * **Costochondral dysplasia:** While Warfarin affects cartilage, "costochondral dysplasia" is not a standard term used to describe the specific stippling seen in Warfarin embryopathy. **NEET-PG High-Yield Pearls:** * **Safe Alternative:** Low Molecular Weight Heparin (LMWH) or Unfractionated Heparin (UFH) are the drugs of choice in pregnancy as they **do not cross the placenta.** * **Critical Period:** Exposure between **6–9 weeks** is most critical for embryopathy. * **Late Pregnancy Risks:** Use in the second/third trimester can lead to fetal CNS hemorrhage and ophthalmic defects (microphthalmia, optic atrophy). * **Breastfeeding:** Warfarin is safe during breastfeeding as it is not excreted in breast milk.

Q: A patient has subclinical folate deficiency. Which of the following drugs can precipitate megaloblastic anemia in such a patient?

Chloroquine. **Explanation:** The correct answer is **Chloroquine**. **Mechanism of Action:** Megaloblastic anemia occurs when DNA synthesis is impaired, typically due to a deficiency in Vitamin B12 or Folate [1]. Chloroquine acts as a **dihydrofolate reductase (DHFR) inhibitor**. In patients with subclinical folate deficiency (borderline stores), the introduction of a DHFR inhibitor further blocks the conversion of dihydrofolate to tetrahydrofolate (the active form). This sudden disruption of the folate cycle halts erythropoiesis, precipitating overt megaloblastic anemia [1]. **Analysis of Incorrect Options:** * **Alcohol:** While chronic alcoholism is a leading cause of folate deficiency (due to poor intake and impaired enterohepatic circulation), it is considered a lifestyle factor/toxin rather than a specific pharmacological precipitant in the context of acute DHFR inhibition. * **Phenytoin:** This anticonvulsant causes folate deficiency primarily by **inhibiting intestinal conjugate enzymes**, thereby reducing the absorption of dietary polyglutamates. It is a chronic cause of deficiency rather than an acute precipitant like DHFR inhibitors [1]. * **Sulfasalazine:** This drug inhibits the **reduced folate carrier (RFC)** and slightly impairs absorption. While it can lower folate levels over time, its potency in precipitating acute megaloblastic crisis is lower compared to direct enzyme inhibitors [1]. **NEET-PG High-Yield Pearls:** * **DHFR Inhibitors (The "M-P-T-C" Mnemonic):** **M**ethotrexate, **P**yrimethamine, **T**rimethoprim, and **C**hloroquine/Cycloguanil. * **Drug-Induced Megaloblastic Anemia:** Always check for drugs that interfere with DNA synthesis (e.g., Hydroxyurea, 5-Fluorouracil, Zidovudine). * **Clinical Note:** In clinical practice, patients on long-term Chloroquine or Methotrexate are often co-prescribed **folinic acid (leucovorin)** to bypass the inhibited DHFR enzyme.

Q: Alteplase acts by which mechanism?

Converting plasminogen to plasmin. **Explanation:** Alteplase is a **recombinant tissue-type plasminogen activator (rt-PA)**. It belongs to the class of **thrombolytic (fibrinolytic) agents**. **1. Why Option A is Correct:** The fundamental mechanism of all thrombolytics is the activation of the endogenous fibrinolytic system. Alteplase binds to fibrin in a thrombus and selectively converts **plasminogen to plasmin**. Plasmin is a serine protease that acts as "molecular scissors," proteolytically digesting the fibrin meshwork of a clot into soluble fragments. **2. Why Incorrect Options are Wrong:** * **Option B:** This describes the *result* of plasmin activity, not the direct mechanism of Alteplase itself. Alteplase is the catalyst that creates the enzyme (plasmin) responsible for this step. * **Option C:** This describes the action of **Thrombin**, which is the final step in the coagulation cascade (clot formation), the exact opposite of what Alteplase achieves. * **Option D:** This describes the mechanism of drugs like **Bevacizumab or Ranibizumab**, used in oncology and ophthalmology (AMD), and has no relation to thrombolysis. **NEET-PG High-Yield Pearls:** * **Fibrin Specificity:** Alteplase, Reteplase, and Tenecteplase are **clot-specific** (fibrin-selective), meaning they preferentially activate plasminogen bound to clots, causing less systemic lytic state compared to Streptokinase. * **Therapeutic Window:** Crucial for "Golden Hour" management. It must be administered within **3–4.5 hours** for Ischemic Stroke and is used for ST-elevation MI (STEMI) if PCI is not available within 90–120 minutes. * **Antidote:** In cases of excessive bleeding due to thrombolytics, **Epsilon-aminocaproic acid or Tranexamic acid** (plasminogen activation inhibitors) can be used.

Q: Which of the following is an oral direct Factor Xa inhibitor?

Rivaroxaban. **Explanation:** The correct answer is **Rivaroxaban**. **1. Why Rivaroxaban is correct:** Rivaroxaban belongs to the class of **Direct Oral Anticoagulants (DOACs)**. It works by binding directly and reversibly to the active site of **Factor Xa**, inhibiting its ability to convert prothrombin to thrombin. A helpful mnemonic to remember this class is that their names contain **"-xa-"** (e.g., Ri-**xa**-roba-**xa**-n, Api-**xa**-ban, Edo-**xa**-ban), signifying their target: Factor **Xa** inhibitor. **2. Why the other options are incorrect:** * **Dabigatran:** While it is an oral anticoagulant, it is a **Direct Thrombin (Factor IIa) Inhibitor**, not a Factor Xa inhibitor. * **Fondaparinux:** This is a synthetic pentasaccharide that inhibits Factor Xa, but it is administered **parenterally** (subcutaneously), not orally. It acts indirectly by binding to Antithrombin III. * **Lepirudin:** This is a parenteral (IV) **Direct Thrombin Inhibitor**, a recombinant derivative of hirudin, primarily used in patients with Heparin-Induced Thrombocytopenia (HIT). **3. High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Unlike Warfarin, DOACs like Rivaroxaban do not require routine PT/INR monitoring. * **Reversal Agent:** The specific reversal agent for Factor Xa inhibitors (Rivaroxaban/Apixaban) is **Andexanet alfa**. (For Dabigatran, it is Idarucizumab). * **Advantages:** They have a rapid onset of action, predictable pharmacokinetics, and fewer drug-food interactions compared to Vitamin K antagonists. * **Excretion:** Rivaroxaban is partially cleared by the kidneys; thus, dose adjustment is required in chronic kidney disease (CKD).

Q: What is a disadvantage of using dextran as a plasma expander?

Interference with blood group matching. Dextrans are high-molecular-weight polysaccharides used as colloidal plasma expanders. The correct answer is **Interference with blood group matching** because dextran molecules coat the surface of red blood cells (RBCs). This coating leads to **pseudo-agglutination**, which interferes with cross-matching and blood grouping procedures [1]. Therefore, it is a standard clinical practice to draw blood for grouping and matching *before* administering dextran. **Analysis of Incorrect Options:** * **B. Causes thrombocytopenia:** Dextran does not typically cause a decrease in platelet count (thrombocytopenia). However, it can cause **platelet dysfunction** by reducing platelet adhesiveness and interfering with Factor VIII/vWF complex, leading to an increased bleeding time. * **C. Decreases microcirculation:** This is incorrect. Dextran (especially Dextran-40 or Low Molecular Weight Dextran) actually **improves microcirculation** by reducing blood viscosity and preventing the sludging of RBCs. * **D. Promotes rouleaux formation:** This is the opposite of its clinical effect. Dextran **decreases rouleaux formation** by increasing the electronegativity of RBCs, causing them to repel each other. **High-Yield Clinical Pearls for NEET-PG:** * **Dextran-70 (Clinical Dextran):** Most commonly used for volume expansion; stays in circulation for ~24 hours. * **Dextran-40 (Rheomacrodex):** Used specifically to improve microcirculation in shock or peripheral vascular surgery; however, it carries a higher risk of **acute renal failure** due to tubular obstruction. * **Anaphylaxis:** Dextran is highly immunogenic and can cause severe hypersensitivity reactions [1]. * **Contraindication:** Avoid in patients with severe bleeding disorders, congestive heart failure, or renal failure.

Q: Which of the following plasminogen activators (fibrinolytics) can be administered as a bolus dose in patients with acute myocardial infarction?

Reteplase. **Explanation:** The correct answer is **Reteplase**. The primary factor determining whether a fibrinolytic can be given as a bolus dose is its **plasma half-life**. **Why Reteplase is correct:** Reteplase is a genetically engineered, non-glycosylated form of recombinant tissue plasminogen activator (rt-PA). It has a longer half-life (approximately 15–18 minutes) compared to native alteplase. This extended duration allows it to be administered as **two intravenous bolus injections** (10 units each, 30 minutes apart) rather than a continuous infusion. This simplifies administration in emergency settings like Acute Myocardial Infarction (AMI). **Why other options are incorrect:** * **Alteplase (rt-PA):** It has a very short half-life (3–5 minutes). Consequently, it requires a complex **"accelerated infusion"** regimen (a small initial bolus followed by a continuous IV infusion over 90 minutes) to maintain therapeutic levels. * **Urokinase:** It is a non-fibrin-specific activator with a short half-life (12–20 minutes) but is traditionally administered via **continuous intravenous infusion** for conditions like pulmonary embolism or peripheral arterial occlusion, rather than a rapid bolus for AMI. **High-Yield NEET-PG Pearls:** 1. **Tenecteplase (TNK-tPA):** This is the most fibrin-specific agent with the longest half-life. It is administered as a **single weight-based IV bolus**, making it the preferred agent for pre-hospital thrombolysis. 2. **Fibrin Specificity:** Alteplase, Reteplase, and Tenecteplase are fibrin-specific (clot-selective), whereas Streptokinase and Urokinase are non-specific (systemic lytic state). 3. **Antigenicity:** Streptokinase is the only highly antigenic agent; it can cause anaphylaxis and cannot be repeated within 6–12 months due to neutralizing antibodies.

Q: Desmopressin nasal spray is most useful in which of the following types of Von Willebrand Disease?

Type 1 VWD. Explanation: Mechanism of Action: Desmopressin (DDAVP) is a synthetic analogue of vasopressin that acts on V2 receptors on endothelial cells [3]. This stimulation triggers the release of pre-stored Von Willebrand Factor (vWF) and Factor VIII from the Weibel-Palade bodies into the plasma. Why Type 1 VWD is the correct answer: Type 1 VWD is characterized by a quantitative deficiency (partial) of vWF, but the protein produced is structurally normal. Because these patients have functional stores of vWF, DDAVP can effectively "squeeze" out these stores to achieve hemostatic levels [4]. It is the treatment of choice for minor surgeries and bleeding episodes in these patients. Analysis of Incorrect Options: * Type 2A VWD: This involves a qualitative defect where vWF is present but lacks high-molecular-weight multimers. While some Type 2 subtypes might show a partial response, it is inconsistent and often inadequate compared to Type 1. (Note: In Type 2B, DDAVP is contraindicated as it can cause transient thrombocytopenia). * Type 3 VWD: This is a total/severe quantitative deficiency of vWF. Since there are virtually no stores of vWF in the endothelial cells, DDAVP has nothing to release and is therefore ineffective. These patients require vWF/Factor VIII concentrate [4]. * Option D: Incorrect because Type 3 is a contraindication/non-responder. High-Yield NEET-PG Pearls: * Route: For VWD, it can be given IV, SC, or as a high-concentration nasal spray (Stimate) [1]. Note that the nasal spray for VWD is 15x more concentrated than the one used for Diabetes Insipidus. * Side Effects: Hyponatremia (due to water retention/antidiuretic effect) [2] and facial flushing. * Tachyphylaxis: Repeated doses lead to diminished response as endothelial stores become exhausted. * Clinical Use: Also used in Mild Hemophilia A (not Hemophilia B) and Enuresis.

Q: Which of the following statements is false about unfractionated heparin?

It inhibits anti-thrombin III. **Explanation:** The core mechanism of **Unfractionated Heparin (UFH)** is its interaction with **Antithrombin III (AT-III)**. Heparin does not inhibit AT-III; instead, it acts as an **indirect thrombin inhibitor** by binding to AT-III and inducing a conformational change that increases its activity by 1,000-fold. Therefore, Heparin **activates** AT-III, which then neutralizes clotting factors. * **Why Option C is False (The Correct Answer):** Heparin is an **agonist/activator** of Antithrombin III, not an inhibitor. AT-III is a natural anticoagulant; inhibiting it would promote clotting, which is the opposite of Heparin’s therapeutic goal. * **Why Option A is True:** Heparin acts directly on clotting factors present in the blood. Unlike Warfarin (which requires liver synthesis of factors and works only *in-vivo*), Heparin works both inside the body and in a test tube (e.g., in blood collection vials). * **Why Options B & D are True:** Once activated by Heparin, the AT-III complex neutralizes several serine proteases. UFH has a long pentasaccharide chain that allows it to inhibit both **Factor Xa** and **Factor IIa (Thrombin)** in a 1:1 ratio. **High-Yield Clinical Pearls for NEET-PG:** 1. **Monitoring:** UFH is monitored using **aPTT** (intrinsic pathway). 2. **Antidote:** **Protamine sulfate** (a basic drug that neutralizes acidic heparin via ion pairing). 3. **Side Effect:** Watch for **HIT (Heparin-Induced Thrombocytopenia)**; if it occurs, switch to Lepirudin or Argatroban. 4. **LMWH vs. UFH:** Low Molecular Weight Heparin (e.g., Enoxaparin) mainly inhibits Factor Xa (ratio 3:1) and does not require routine aPTT monitoring.

Question 1

When heparin is given during pregnancy, it should be supplemented with which of the following?

Accepted Answer

Calcium

Answer

Zinc

Answer

Folic acid

Answer

Ferrous sulphate

Question 2

Oral anticoagulants given to pregnant women can cause which of the following fetal malformations?

Accepted Answer

Craniofacial malformation

Answer

Long bones limb defect

Answer

Cardiovascular malformation

Answer

Costochondral dysplasia

Question 3

A patient has subclinical folate deficiency. Which of the following drugs can precipitate megaloblastic anemia in such a patient?

Accepted Answer

Chloroquine

Answer

Alcohol

Answer

Phenytoin

Answer

Sulfasalazine

Question 4

Alteplase acts by which mechanism?

Accepted Answer

Converting plasminogen to plasmin

Answer

Converting fibrin to fibrin degradation products

Answer

Converting fibrinogen to fibrin

Answer

Blocking VEGF receptor

Question 5

Which of the following is an oral direct Factor Xa inhibitor?

Accepted Answer

Rivaroxaban

Answer

Dabigatran

Answer

Fondaparinux

Answer

Lepirudin

Question 6

What is a disadvantage of using dextran as a plasma expander?

Accepted Answer

Interference with blood group matching

Answer

Causes thrombocytopenia

Answer

Decreases microcirculation

Answer

Promotes rouleaux formation

Question 7

Which of the following plasminogen activators (fibrinolytics) can be administered as a bolus dose in patients with acute myocardial infarction?

Accepted Answer

Reteplase

Answer

Urokinase

Answer

Alteplase

Answer

None of the above

Question 8

Desmopressin nasal spray is most useful in which of the following types of Von Willebrand Disease?

Accepted Answer

Type 1 VWD

Answer

Type 2A VWD

Answer

Type 3 VWD

Answer

Type 1 & Type 3 VWD

Question 9

Which of the following statements about prasugrel is true when compared to clopidogrel?

Accepted Answer

Due to a high risk of bleeding, prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack.

Answer

It has a slower onset of action than clopidogrel.

Answer

It is a reversible antagonist of the ADP receptor.

Answer

It is effective orally, unlike clopidogrel.

Question 10

Which of the following statements is false about unfractionated heparin?

Accepted Answer

It inhibits anti-thrombin III

Answer

It is effective both in-vitro and in-vivo

Answer

It inhibits factor Xa

Answer

It inhibits factor IIa

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?